Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre …
1. 系统已在2026-05-13 11:33:24对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
求这篇文章的补充材料supplement
M Noureddin, SA Harrison, R Loomba, N Alkhouri…
The Lancet, 2025
thelancet.com
Background GLP-1–glucagon dual receptor agonists such as pemvidutide have shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH). The aim of this trial was to assess the effects of pemvidutide on MASH resolution and fibrosis improvement in patients with liver fibrosis stage F2 or F3 MASH at 24 weeks of treatment. Methods IMPACT is an ongoing 48-week international, randomised, double-blind, placebo-controlled, phase 2b trial in patients with biopsy-confirmed MASH and fibrosis stage F2 or F3. Patients …
